Anika Therapeutics, Inc.ANIKNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank21
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P21
Within normal range
vs 5Y Ago
-0.2x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
2025-11.64%
2024-7.29%
202316.97%
2022-30.86%
202123.36%
202071.85%
20191.79%
201859.41%
201719.58%
201621.50%